GOLD 2017: A New Report

Chest

Volumn 151, Issue 2, 2017, Pages 245-246

  Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; INFLUENZA VACCINE; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; PNEUMOCOCCUS VACCINE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; EDITORIAL; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INHALER; RISK FACTOR; SMOKING; SPIROMETRY; TUBERCULOSIS; COMPLICATION; PRACTICE GUIDELINE;

HUMANS; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 85011580018     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2016.11.042     Document Type: Editorial

References (16)

1. 1 Global Initiative for Chronic Obstructive Lung Disease (GOLD): global strategy for the diagnosis, management and prevention of COPD. www.goldcopd.org. Accessed December 19, 2016.
2. 2 Soriano, J.B., Lamprecht, B., Ramirez, A.S., et al. Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. Lancet Resp Med 3:6 (2015), 443–450.
3. 3 Woodruff, P.G., Barr, R.G., Bleecker, E., et al. Clinical significance of symptoms in smokers with preserved pulmonary function. N Engl J Med 374:19 (2016), 1811–1821.
4. 4 Rodriguez-Roisin R, Han MK, Vestbo J, Wedzicha JA, Woodruff PG, Martinez FJ. Chronic respiratory symptoms with normal spirometry: a reliable clinical entity [published online ahead of print September 6, 2016]? Am J Respir Crit Care Med. http://dx.doi.org/10.1164/rccm.201607-1376PP.
5. 5 Allinson, J.P., Hardy, R., Donaldson, G.C., Shaheen, S.O., Kuh, D., Wedzicha, J.A., The presence of chronic mucus hypersecretion across adult life in relation to chronic obstructive pulmonary disease development. Am J Respir Crit Care Med 193:6 (2016), 662–672.
6. 6 Martinez, F.D., Early-life origins of chronic obstructive pulmonary disease. N Engl J Med 375:9 (2016), 871–878.
7. 7 Lange, P., Celli, B., Agusti, A., et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med 373:2 (2015), 111–122.
8. 8 Gordon, S.B., Bruce, N.G., Grigg, J., et al. Respiratory risks from household air pollution in low and middle income countries. Lancet Resp Med 2:10 (2014), 823–860.
9. 9 Byrne, A.L., Marais, B.J., Mitnick, C.D., Lecca, L., Marks, G.B., Tuberculosis and chronic respiratory disease: a systematic review. Int J Infect Dis 32 (2015), 138–146.
10. 10 Mirsaeidi, M., Ebrahimi, G., Allen, M.B., Aliberti, S., Pneumococcal vaccine and patients with pulmonary diseases. Am J Med 127:9 (2014), 886.e881–886.e888.
11. 11 Vincken, W., Dekhuijzen, P.R., Barnes, P., The ADMIT series—issues in inhalation therapy. 4) How to choose inhaler devices for the treatment of COPD. Prim Care Respir J 19:1 (2010), 10–20.
12. 12 Pavord, I.D., Lettis, S., Anzueto, A., Barnes, N., Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. Lancet Resp Med 4:9 (2016), 731–741.
13. 13 Kruis, A.L., Boland, M.R., Assendelft, W.J., et al. Effectiveness of integrated disease management for primary care chronic obstructive pulmonary disease patients: results of cluster randomised trial. BMJ, 349, 2014, g5392.
14. 14 Sciurba, F.C., Chandra, D., Bon, J., Bronchoscopic lung volume reduction in COPD: lessons in implementing clinically based precision medicine. JAMA 315:2 (2016), 139–141.
15. 15 Barnes, P.J., Mechanisms of development of multimorbidity in the elderly. Eur Respir J 45:3 (2015), 790–806.
16. 16 National Institute of Clinical Excellence. Multimorbidity: clinical assessment and management. https://www.nice.org.uk/guidance/indevelopment/gid-cgwave0704/documents. Accessed December 1, 2016.